Last reviewed · How we verify
R115777
At a glance
| Generic name | R115777 |
|---|---|
| Also known as | NSC-702818, Zarnestra, tipifarnib |
| Sponsor | SWOG Cancer Research Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (PHASE2)
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (PHASE1, PHASE2)
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (PHASE2)
- Expanded Access to Tipifarnib
- Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS (PHASE2)
- Tipifarnib in Subjects With Myelodysplastic Syndromes (PHASE2)
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R115777 CI brief — competitive landscape report
- R115777 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI